Aktis Oncology (AKTS) COO details stock option grants and vesting

Rhea-AI Filing Summary

Aktis Oncology Chief Operating Officer Shulamit Ron-Bigger reported her existing stock option holdings in a Form 3 insider ownership filing. The filing lists stock options to purchase 267,888 shares of common stock at $3.66 per share expiring on 10/30/2032, 18,697 shares at $4.95 expiring on 06/30/2034, 118,284 shares at $9.33 expiring on 10/10/2034, and 131,426 shares at $18 expiring on 01/07/2036, all held directly.

For three grants, 25% of the original option amount either has vested or is scheduled to vest on specific dates, with the remaining portions vesting in equal monthly installments over 48 months, as long as Ron-Bigger continues in service. This filing establishes her baseline equity position as an officer of Aktis Oncology.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ron-Bigger Shulamit

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	10/30/2032	Common Stock	267,888	$3.66	D
Stock Option (Right to Buy)	(1)	06/30/2034	Common Stock	18,697	$4.95	D
Stock Option (Right to Buy)	(2)	10/10/2034	Common Stock	118,284	$9.33	D
Stock Option (Right to Buy)	(3)	01/07/2036	Common Stock	131,426	$18	D

Explanation of Responses:

1. 25% of the original number of shares subject to the option vested on September 19, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

2. 25% of the original number of shares subject to the option vested on October 9, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

3. 25% of the original number of shares subject to the option shall vest on January 8, 2027, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Shulamit Ron-Bigger	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Aktis Oncology (AKTS) Form 3 filing show for the COO?

The Form 3 shows that Chief Operating Officer Shulamit Ron-Bigger directly holds multiple stock options to purchase Aktis Oncology common stock with different exercise prices and expiration dates.

How many Aktis Oncology shares are covered by the COOs reported stock options?

The filing lists options covering 267,888 shares at $3.66, 18,697 shares at $4.95, 118,284 shares at $9.33, and 131,426 shares at $18 of Aktis Oncology common stock.

When do the COOs Aktis Oncology stock options expire?

The reported stock options expire on 10/30/2032, 06/30/2034, 10/10/2034, and 01/07/2036, depending on the specific grant.

How do the vesting schedules work for the Aktis Oncology COO stock options?

For three grants, 25% of the original option amount vested or will vest on specific dates, and the remaining 75% vests in 1/48th monthly installments, subject to continuous service.

Is the Aktis Oncology COOs ownership in this Form 3 direct or indirect?

The Form 3 indicates that the reported stock options are held directly (D) by Shulamit Ron-Bigger, with no indirect ownership entity noted.

Does this Aktis Oncology Form 3 indicate any new stock option transactions?

The Form 3 characterizes the entries as holdings, meaning it discloses the COOs existing stock option positions rather than reporting new purchases or sales.